tbuckley/cabot-search huggingface dataset:
Limited usage of T-cell receptor ? chains and sequences of the complementarity determining region 3 of lymphocytes infiltrating in the liver of autoimmune hepatitis
Authors: Y HOSHINO
Journal: Hepatology (1995)

To study the role of antigen-specific T lymphocytes in the pathogenesis of autoimmune hepatitis, messenger RNA of T-cell receptors (TCR) was analyzed in liver biopsy specimens from four patients with autoimmune hepatitis. Using the TCR β-chain variable region family specific oligonucleotides, a remarkable bias for the usage of β-chain variable region 3 was detected in all four patients. Therefore, nucleotide and amino acid sequences of the complementarity-determining region 3 rearranged to the β-chain variable region 3, which is a putative contact site for peptide fragments from antigens bound in the groove of the human leukocyte antigen molecule, was further analyzed in randomly selected 10 clones from each patient. An Asp-Arg-Pro motif in the complementarity-determining region 3 was identified in three of four patients with human leukocyte antigen DR4, and this motif was always rearranged to the β-chain junctional region 1.2. From these results, β-chain variable region 3+, Asp-Arg-Pro+ β-chain junctional region 1.2+ T-cell clones may be among the responsible lymphocytes involved in the liver damage in autoimmune hepatitis, especially in patients with human leukocyte antigen DR4. Thus, an analysis of the complementarity-determining region 3 may give us an important clue to clarify characteristics of target antigens included in autoimmune hepatitis. (HEPATOLOGY 1995; 22:142–147.)
The Cover
Authors: Mark S. Litwin
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nitrofurantoin
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl).
Authors: Carmen Joseph Allegra, Josep Tabernero, Philippe Rougier, Giorgio Scagliotti, Philip Agop Philip, Radek Lakomy, Rodryg Ramlau, Sylvie Assadourian, Soazig Chevalier, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2012)

561 Background: Three Db Pbo controlled studies were conducted with IV Afl in metastatic cancer patients [colorectal (CRC) Afl+FOLFIRI (WCGC 2011 abstract O-0024), lung (LC) Afl+docetaxel (WCLC 2011, abstract 511) and pancreatic (PC) Afl+gemcitabine (WCGC 2009 abstract O-0006)]. Each study used the same weekly Afl dose intensity (4 mg/kg q2w for CRC and PC; 6mg/kg q3w for LC). A safety meta-analysis of anti-VEGF class adverse events (AE) was performed on data from these studies. Methods: A fixed-effect logistic regression model was used, including study, treatment and study-by-treatment interaction factors as covariates to test the consistency of treatment effect across studies for each of the considered AE. When no evidence of heterogeneity of treatment effects was found across studies, relative risks (RR) and 95% confidence intervals (CI) were estimated. Summary incidences (% of patients [pts]) and RR are presented for NCI grade 3-4 events. Results: Safety data from total of 2,662 pts (Afl: 1,333; Pbo: 1,329) were included for analysis (Table). Among pts treated with Afl, 0.4 and 0.5% experienced grade 4 hypertension and nephrotic syndrome, respectively. Conclusions: The addition of Afl to concurrent chemotherapies did not increase the risk of VTE. The risk of grade 3-4 anti-VEGF class AEs was increased when adding Afl to concurrent chemotherapies. This increased risk was statistically significant ( ** ) only for hypertension, proteinuria and hemorrhage. Further analyses, when more data are available, should improve the precision of these results. Studies were sponsored by Sanofi NCT00561470 , NCT00532155 , and NCT00574275 . [Table: see text]
Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Authors: C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna, T Barbui
Journal: Leukemia (2017)
Correction
Journal: BMJ (1952)

ANY QUESTIONS?MFDICAL BOURNAL tives for lean beef are: lean mutton, lean veal, liver, heart,rabbit, chicken, rationed cheese (cheddar type).Calcium, iron, and vitamin supplements (A, B complex, C, D) are necessary.The actual vitamin content of fruits and vege- tables is always doubtful.Food yeast, which is a good source of vitamin-B group, can be used to improve the flavour of the skimmed milk.Once pregnancy toxaemia has established itself the follow- ing 1,200-calorie diet should be advised: 1 pint skimmed milk daily.Breakfast: tea or coffee with milk (no sugar), 1+ oz.salt-free bread, i oz.salt-free butter, 1 egg, 4 oz.fruit or tomalo.Mid-morning: tea or coffee with milk (no sugar).Lunch: 2 oz.lean beef or equivalent (see 1,800- -calorie diet above), 6 oz.green vegetable, 5 oz.root vege- table, i oz.margarine for vegetables, 4 oz.fruit.Tea: tea
AN OPPOSER OF MEDICAL PRACTICE ACTS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Law and medicine
Authors: L. O. Gostin
Journal: JAMA (1995)

The conventional view that physician-assisted death represents a legal and moral wrong is being reexamined in state referenda and the judiciary. Ballot Measure 16 in Oregon passed, making the state the first to specifically authorize physicians to prescribe drugs to end the life of a terminally ill patient who makes a voluntary, informed choice. The initiative allows an adult with 6 months to live to request a prescription for a lethal dose of drugs; two physicians must certify that the patient is terminally ill, and the patient must request the prescription three times, the last time in writing. The physician must wait 15 days before writing the prescription.<sup>1</sup>On December 7, 1994, a federal district court judge issued a temporary restraining order blocking implementation of the law. The order was based on constitutional grounds that the law provides inadequate safeguards for persons with depression and draws an impermissible distinction
CLASSIFICATION AND SURGICAL TREATMENT OF ACUTE PERITONITIS.
Authors: N. SENN
Journal: JAMA (1897)

<h3>Methods of drainage.</h3> —At present there are three methods of drainage in general use: 1. Tubular drainage. 2. Capillary drainage. 3. A combination of tubular and capillary drainage. All of these methods have their advocates and are applicable under certain circumstances. No one method of drainage will answer in all cases. <h3>Tubular drainage.</h3> —Tubular drainage is specially indicated in cases in which the abdominal cavity contains pus. The tubes employed are made either of glass or soft rubber. Keith's glass drains answer an excellent purpose in draining the lowest portion of the abdominal cavity. They should be slightly curved at the abdominal end so as to reach the floor of the pelvic cavity without making harmful pressure against the bladder. Frequent aspiration of the contents of the drain is necessary for the purpose of removing the fluid inflammatory product as soon as it is formed. The rubber drain answers the
SHP2 Converts Parafibromin/Cdc73 from Tumor Suppressor to Oncoprotein
Journal: Cancer Discovery (2011)

SHP2 is a ubiquitously expressed protein tyrosine phosphatase encoded by the PTPN11 gene. Mutations in PTPN11 are associated with the hereditary developmental disorder Noonan syndrome in addition to adult and juvenile leukemia. SHP2 plays a central role in cell signaling events that promote growth and motility and is required for activation of the RAS signaling pathway. Deregulation of SHP also has been implicated in the development of multiple human malignancies. In a recent article, Takahashi and colleagues identified a unique role for SHP2 in the nucleus, as the determinant of the function of parafibromin/Cdc73, a component of the nuclear RNA polymerase II-associated factor (PAF) complex. Parafibromin has opposing functions that are context dependent. When complexed with the histone methyltransferase SUV39H1, parafibromin acts as a tumor suppressor that inhibits the transcription of cyclin D1 and c-myc. However, upon binding β-catenin, parafibromin switches to an oncogene that activates the promitogenic Wnt signaling pathway. The authors discovered that parafibromin is a unique substrate of SHP2 and that dephosphorylation by SHP2 determines its binding partner and therefore its nuclear function. In the absence of SHP2, parafibromin was tyrosine-phosphorylated and complexed with SUV39H1. Upon tyrosine dephosphorylation by SHP2, parafibromin preferentially bound to and trapped β-catenin in the nucleus. The formation and nuclear accumulation of the stable parafibromin/β-catenin complex was able to override parafibromin/SUV39H1-mediated repression and led to the induction of Wnt target genes. Overall, the important finding that SHP2 activity determines whether parafibromin behaves as a tumor suppressor or an oncogene offers mechanistic insight into how the deregulation of SHP2 may play a causative role in the development of neoplasms and developmental malformations.Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell 2011;43:45–56.Note: Research Watch is written by Cancer Discovery Editors. Readers are encouraged to consult the articles referred to in each item for full details on the findings described.
Would the real mccoy please stand up?
Journal: Hepatology (1994)

Sera from patients with primary biliary cirrhosis (PBC) react with enzymes of the 2-oxo dehydrogenase pathways, particularly PDC-E2. These enzymes are present in all nucleated cells, yet autoimmune damage is confined to biliary epithelial cells. Using a panel of eight mouse monoclonal antibodies and a human combinatorial antibody specific for PDC-E2, we examined by indirect immunofluorescence and confocal microscopy sections of liver from patients with PBC, progressive sclerosing cholangitis, and hepatocarcinoma. The monoclonal antibodies gave typical mitochondrial immunofluorescence on biliary epithelium and on hepatocytes from patients with either PBC, progressive sclerosing cholangitis, or hepatocarcinoma. However, one of eight mouse monoclonal antibodies (C355.1) and the human combinatorial antibody reacted with great intensity and specificity with the luminal region of biliary epithelial cells from patients with PBC. Simultaneous examination of these sections with an antiisotype reagent for human IgA revealed high IgA staining in the luminal region of biliary epithelial cells in patients with PBC. IgG and IgA antibodies to PDC-E2 were detected in the bile of patients with PBC but not normal controls. We believe that this data may be interpreted as indicating that a molecule cross-reactive with PDC-E2 is expressed at high levels in the luminal region of biliary epithelial cells in PBC.
Delay In Recognizing Cancer Studied
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Monthly Problem in Cutaneous Medicine
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review A True History of the Terrible Epidemic Vulgarly Called the Throat Distemper Which Occurred in His Majesty's New England Colonies between the Years 1735 and 1740 . By Ernest Caulfield, M.D. 8°, half cloth, 113 pp., with illustrations. New Haven, Conn.: published for the Beaumont Medical Club by the Yale Journal of Biology &amp; Medicine, 1939. $2.50.
Journal: New England Journal of Medicine (1940)
The Chemical Composition of Standard Cotton Dust
Authors: Linda N. Domelsmith, Ralph J. Berni
Journal: Environmental Health Perspectives (1986)

Cotton dust samples from Cotton Incorporated were investigated by X-ray fluorescence and proximate analysis methods. These dust samples are known as "standard cotton dust" and have been used by many researchers investigating the causative agent(s) and physiological mechanisms of byssinosis. Silicon, calcium, potassium, and aluminum were present in relatively high concentrations (1-4%) in the dust fractions. The ash content of the dust fractions increased as the fraction particle size decreased. Proximate analyses demonstrate that "noncellulosic organics" are the major class of constituents (35-45%) in cotton dust. Cellulose comprises only 10-15% of the dust, while water-extractable materials comprise approximately 20% of the dust. Capillary gas chromatography performed on silylated, freeze-dried, aqueous extracts of the less than or equal to 38 micron dust fraction revealed the presence of phosphate, malate, arabitol, citrate, fructose, glucose, and mannitol.
NECROLOGY.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
Authors: Timothy Jay Price, Lin Shen, Brigette Ma, Regina Esser, Wen-Feng Chen, Peter Gibbs, Robert S.C. Lim, Ann-Lii Cheng
Journal: Journal of Clinical Oncology (2018)

3534 Background: In the RAS wt population of APEC, q2w cetuximab combined with first-line FOLFOX or FOLFIRI achieved an overall response rate (ORR), median progression-free survival (PFS), and median overall survival (OS) similar to those reported in prior first-line pivotal studies involving weekly cetuximab. In this subgroup analysis, we evaluated the impact of tumor side in the APEC study population with RAS wt mCRC. Methods: APEC was a nonrandomized phase 2 trial conducted in the Asia-Pacific region, with ORR as the primary endpoint. Patients with KRAS exon 2 wt tumors received q2w cetuximab + investigator’s choice of FOLFOX or FOLFIRI. Tumor side was categorized in evaluable patients with RAS wt tumors (left [L]-sided = splenic flexure, descending colon, sigmoid colon, and rectum; right [R]-sided = appendix, cecum, ascending colon, hepatic flexure, and transverse colon). Results: Among 167 patients with RAS wt mCRC, 159 were evaluable for tumor side; 130 (81.8%) had L-sided and 29 (18.2%) had R-sided mCRC. Baseline characteristics in the tumor side subgroups reflected the known differences between L- and R-sided mCRC; indeed, 95.4% and 75.9% of patients had BRAF wt disease, respectively. Efficacy data are summarized in the Table. Conclusions: Consistent with prior first-line pivotal studies with weekly cetuximab, a prognostic effect of tumor side in patients receiving first-line q2w cetuximab was confirmed in APEC. In patients with R-sided mCRC, ORR remained ≥ 50%, and resection rate was comparable to that of L-sided patients, in line with prior evidence showing that use of cetuximab may be appropriate when rapid tumor shrinkage is the goal. These hypothesis-generating data raise the possibility of a synergy between cetuximab and irinotecan in patients with R-sided tumors, although numbers are small. Clinical trial information: NCT00778830. L-side R-side Cetuximab + FOLFIRI Cetuximab + FOLFOX Total Cetuximab + FOLFIRI Cetuximab + FOLFOX Total n 43 87 130 10 19 29 ORR, % 74.4 65.5 68.5 50.0 52.6 51.7 Median PFS, months 12.8 14.2 14.0 15.4 8.3 8.9 Median OS, months 31.7 30.6 30.6 32.1 21.8 24.6 Resection rate, % 2.3 14.9 10.8 10.0 10.5 10.3
Discussion: session 5. Epidemiologic investigation of special groups
Authors: David Parkinson, Vilma Hunt, Jennie Kline, Edmond Murphy
Journal: Environmental Health Perspectives (1981)

opened the discussion by reading a letter to a member of the Steelworkers Union from his employer, stating that the worker's employment had been termi- nated because "extensive testing conducted by our [the company's] physicians has indicated that you [the worker] have unusual propensity to absorb certain amounts of lead in your bloodstream and tissues."The letter went on to state that the worker had a greater response of blood lead than other workers with similar exposures, and because temporary removal from the work environment was not a permanent solution to the problem, the company was terminating his employment.Yet two months previously the worker had been notified that his exposure to lead had been to 21,224 ,ug/m3, way above the current 8-hr standard of 100 ,ug/m3; thus the worker's elevated blood lead had a clear basis from excessive exposure, and was not simply a propensity to absorb more.Dr. Parkinson therefore questioned the value of research on hypersusceptibility to environmental agents.He thought that this meeting showed that epidemiology could not help in providing clean conditions in the workplace, and that perhaps the money spent on epidemiological research would be better spent in preventive measures to protect workers before they are irreparably damaged.Dr. Hunt replied that we are all concerned about these issues, but made a distinction between